Want to see JP:7133 full AI Analyst Report?
Top Page
HYUGA PRIMARY CARE Co.,Ltd.
(7133)
Select Model
Select Model
Rating:59Neutral
Price Target:
¥1,270.00
▲(10.43% Upside)
Action:Reiterated
Date:07/14/26
The score is held back primarily by weakening profitability, elevated leverage, and a sharp deterioration in cash generation (free cash flow nearly breakeven) despite strong revenue growth. Technicals are supportive with a clear uptrend, but overbought indicators increase near-term risk. Valuation is moderate with a modest dividend yield.
Positive Factors
Sustained Revenue Growth
Consistent double-digit top-line growth (2026 accelerating to ~16%) shows durable demand for its pharmacy services and expanding scale. That recurring fee-based revenue under Japan's reimbursement framework supports long-term cash flow potential and strategic reinvestment capacity.
Negative Factors
Margin Compression
Meaningful gross and net margin deterioration in 2026 signals rising cost pressures or adverse mix that erode unit economics. Persistent margin weakness would impair free cash flow, reduce reinvestment capacity and weaken the stability of returns even with revenue growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Growth
Consistent double-digit top-line growth (2026 accelerating to ~16%) shows durable demand for its pharmacy services and expanding scale. That recurring fee-based revenue under Japan's reimbursement framework supports long-term cash flow potential and strategic reinvestment capacity.
Read all positive factors
HYUGA PRIMARY CARE Co.,Ltd. (7133) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥9.53B
Dividend Yield1.54%
Average Volume (3M)16.77K
Price to Earnings (P/E)15.1
Beta (1Y)0.29
Revenue Growth22.80%
EPS Growth-10.77%
CountryJP
Employees882
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)70.38
Shares Outstanding7,282,000
10 Day Avg. Volume17,690
30 Day Avg. Volume16,766
Financial Highlights & Ratios
PEG Ratio-0.51
Price to Book (P/B)2.84
Price to Sales (P/S)0.65
P/FCF Ratio216.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)179.3
Revenue Forecast (FY)¥13.20B
HYUGA PRIMARY CARE Co.,Ltd. Business Overview & Revenue Model
Company Description
HYUGA PRIMARY CARE Co.,Ltd., established in 2007 and based in Kasuga, Japan, specializes in delivering a variety of primary care services, encompassing home-visit pharmacies, nursing support, and personalized care planning. The company extends its...
How the Company Makes Money
HYUGA PRIMARY CARE’s earnings are primarily derived from fees generated through its pharmacy-related operations. Key revenue streams typically include (i) prescription dispensing and related service fees paid under Japan’s medical/pharmaceutical r...
HYUGA PRIMARY CARE Co.,Ltd. Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
56
Neutral
Cash Flow
38
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 11.98B | 9.98B | 8.29B | 6.66B | 5.78B |
| Gross Profit | 2.25B | 2.41B | 1.88B | 1.56B | 1.24B |
| EBITDA | 1.18B | 1.31B | 854.38M | 627.27M | 568.69M |
| Net Income | 501.88M | 719.03M | 441.03M | 382.88M | 328.45M |
Balance Sheet | |||||
| Total Assets | 8.29B | 7.05B | 6.35B | 2.92B | 2.54B |
| Cash, Cash Equivalents and Short-Term Investments | 1.02B | 565.93M | 688.01M | 567.69M | 719.56M |
| Total Debt | 3.22B | 2.65B | 2.80B | 251.54M | 330.21M |
| Total Liabilities | 5.56B | 4.68B | 4.71B | 1.44B | 1.46B |
| Stockholders Equity | 2.73B | 2.37B | 1.64B | 1.48B | 1.07B |
Cash Flow | |||||
| Free Cash Flow | 35.71M | 485.51M | 473.20M | 102.59M | 228.92M |
| Operating Cash Flow | 492.94M | 771.32M | 706.64M | 342.25M | 484.60M |
| Investing Cash Flow | -319.13M | -473.98M | -1.13B | -383.39M | -320.25M |
| Financing Cash Flow | 281.88M | -419.43M | 538.78M | -110.73M | 16.93M |
HYUGA PRIMARY CARE Co.,Ltd. Technical Analysis
Positive
1150.00
Price Trends
1192.04
Positive
1117.39
Positive
1112.57
Positive
Market Momentum
34.82
Positive
68.16
Neutral
42.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7133, the sentiment is Positive. The current price of 1150 is below the 20-day moving average (MA) of 1271.35, below the 50-day MA of 1192.04, and above the 200-day MA of 1112.57, indicating a bullish trend. The MACD of 34.82 indicates Positive momentum. The RSI at 68.16 is Neutral, neither overbought nor oversold. The STOCH value of 42.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7133.
HYUGA PRIMARY CARE Co.,Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | ¥40.51B | 12.95 | ― | 0.91% | 6.17% | -33.01% | |
59 Neutral | ¥9.53B | 15.05 | ― | 1.80% | 22.80% | -10.77% | |
56 Neutral | ¥2.50B | 29.72 | ― | 2.56% | -5.72% | -73.78% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | ¥5.48B | 52.37 | ― | 4.07% | 4.85% | -85.27% | |
46 Neutral | ¥4.11B | 12.30 | ― | 1.41% | 14.91% | -39.00% |
* General Sector Average
JP:7133
HYUGA PRIMARY CARE Co.,Ltd.
1,298.00
11.19
0.87%
JP:2373
Care Twentyone Corporation
408.00
5.65
1.40%
JP:2425
Care Service Co., Ltd.
661.00
-120.55
-15.42%
JP:7061
Japan Hospice Holdings Inc.
480.00
-805.84
-62.67%
JP:7071
Amvis Holdings.Inc.
417.00
-214.82
-34.00%
HYUGA PRIMARY CARE Co.,Ltd. Corporate Events
HYUGA PRIMARY CARE outlines FY2026 results and medium-term outlook
May 28, 2026
HYUGA PRIMARY CARE Co., Ltd., a primary care-focused healthcare provider listed on the TSE Growth Market, reported its financial results for the fiscal year ended March 2026. The company outlined its current business profile and operations as part...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.